Researchers characterize regions of DNA that impact MECP2 expression news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Proteomics analysis from aggressive human cancers can help identify potential therapeutic targets
Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.
They report in the journal
Oncogene, the identification of proteomic signatures that are associated with clinical measures of aggressive disease for each of the seven cancer types studied. Some signatures were shared between different types of cancer and included cellular pathways of altered metabolism. Importantly, experimental results provided proof-of-concept that their proteomics analysis approach is a valuable strategy to identify potential therapeutic targets.
E-Mail
Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets. They report in the journal
Oncogene, the identification of proteomic signatures that are associated with clinical measures of aggressive disease for each of the seven cancer types studied. Some signatures were shared between different types of cancer and included cellular pathways of altered metabolism. Importantly, experimental results provided proof-of-concept that their proteomics analysis approach is a valuable strategy to identify potential therapeutic targets. There are two notable aspects of this study. One is that we explored the proteomic landscape of cancer looking for proteins that were expressed in association with aggressive forms of cancer, said co-corresponding author Dr. Chad Creighton, professor of medicine and co-director of Cancer Bioinformatics
Natural reinfection with respiratory syncytial virus varies based on antibody response
Researchers at Baylor College of Medicine found that while most individuals responded to respiratory syncytial virus (RSV) natural reinfection with a typical sustained antibody response associated with protection, a few individuals surprisingly responded atypically, not being able to sustain the antibody response, which declined to levels that made the individuals susceptible to RSV reinfection.
The researchers highlight in their study, published in the journal
Vaccine, that their findings point at a subpopulation of people who also may not maintain an antibody response to vaccines and suggest the need to characterize patient-specific responses to respiratory viral infections, such as COVID-19.